Psychedelics Celebrates First Business Conference
The early days feeling remains for psychedelics investing, but its momentum may be solidifying after industry stakeholders gathered at a first-of-its-kind extensive business conference.
Archives: news
Will Smith reveals ayahuasca use during split from Jada Pinkett Smith in memoir
‘I was trillions of light years from earth,’ says the actor in his new autobiography.
EMA Grants Nova Mentis Life Sciences Corp’s Fragile X Syndrome Psilocybin Drug Orphan Drug Status
Nova Mentis Life Sciences Corp has announced that the European Medicines Agency has granted it an Orphan Drug Designations for its novel psilocybin drug for fragile X syndrome treatment. FXS is the main genetic cause of autism spectrum disorder related symptoms.
Delic Acquires Arizona-Based Ketamine Wellness Centers For US$10 Million
Delic Holdings Corp. announced this morning that it has completed the acquisition of Ketamine Wellness Centers Arizona LLC. The aggregate purchase price for the transaction is US$10 million.
Herbal Supplement Giant To Enter THC, Psychedelics Industries, Seeking To Become First Household Brand To Do So
Irwin Naturals, a publicly traded herbal supplements company that has been around for almost 30 years, is getting into the THC and psychedelics industries.
Compass Pathways’ Phase IIb psilocybin trial shows reduced depression symptoms
UK biotech Compass Pathways revealed this morning that they reached the primary endpoint in a Phase IIb clinical trial of psilocybin therapy.
Study: Mixing CBD With Ketamine Might Be Great For Depression
According to recently published research, by mixing ketamine with cannabidiol, or CBD, the less-psychoactive cannabinoid associated with anti-anxiety and anti-inflammatory benefits, it may be possible to limit unwanted side effects of ketamine therapy.
PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, today provides an update on the ongoing research studies with its novel microneedle (“MN”) patch as a next generation delivery technology for psychedelics, including ketamine, psilocybin, 3,4-methylenedioxy-methamphetamine (“MDMA”), lysergic acid diethylamide (“LSD”), and N, N-dimethyltryptamine (“DMT”).
Algernon Pharmaceuticals reports positive pre-clinical data on DMT candidate to treat stroke
The drug-repurposing firm is researching AP-188 (N,N-Dimethyltryptamine, or DMT), a psychedelic compound, as a potential treatment for the rehabilitation of stroke.
IBN (InvestorBrandNetwork) and PsychedelicNewsWire to Further Collaborate with Microdose Psychedelic Insights for the Upcoming Wonderland Miami Conference
IBN, a multifaceted financial news and publishing company, today announces that it will be collaborating with Microdose Psychedelic Insights for the upcoming Wonderland Miami Conference, which will be held at Miami’s Adrienne Arsht Center for the Performing Arts on Nov. 8-9, 2021.